GT Biopharma, Inc. (GTBP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 25K 50K 75K Q3 '14: 69K Q4 '14: 61K Q1 '15: 68K Q2 '15: 63K Q3 '15: 60K Q4 '15: 27K Q1 '16: 20K Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '14 Q3 '15 Q2 '16 Q1 '17 Q4 '17 Q4 '20 Q3 '21

Gross Profit TTM

0 100K 200K 300K Q3 '13: 281K Q4 '13: 142K Q1 '14: 123K Q2 '14: 87K Q3 '14: 25K Q4 '14: 4K Q1 '15: 11K Q2 '15: 23K Q3 '15: 25K Q4 '15: 27K Q1 '16: 20K Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q4 '13 Q3 '14 Q2 '15 Q1 '16 Q4 '16 Q3 '17 Q2 '18

Operating Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '21: -41.5M Q4 '21: -57.5M Q1 '22: -34M Q2 '22: -32.6M Q3 '22: -33.7M Q4 '22: -21.3M Q1 '23: -19.5M Q2 '23: -20.1M Q3 '23: -16.2M Q4 '23: -13.6M Q1 '24: -13M Q2 '24: -13.3M Q3 '24: -13.8M Q4 '24: -14.4M Q1 '25: -13.2M Q2 '25: -10.8M Q3 '25: -10.6M Q4 '25: -12.4M Q1 '26: -13.3M Q2 '26: -16.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '21: -31.3M Q4 '21: -58M Q1 '22: -33.8M Q2 '22: -31.9M Q3 '22: -33.3M Q4 '22: -20.9M Q1 '23: -15.7M Q2 '23: -14.7M Q3 '23: -10.2M Q4 '23: -7.6M Q1 '24: -9.6M Q2 '24: -11.4M Q3 '24: -12.3M Q4 '24: -13.2M Q1 '25: -11.7M Q2 '25: -38.1M Q3 '25: -26.4M Q4 '25: -30.2M Q1 '26: -32.2M Q2 '26: -6.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 100K 200K 300K Q3 '13: 265K Q4 '13: 226K Q1 '14: 157K Q2 '14: 162K Q3 '14: 44K Q4 '14: 57K Q1 '15: 57K Q2 '15: 40K Q3 '15: 35K Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q4 '13 Q3 '14 Q2 '15 Q1 '16 Q4 '16 Q3 '17 Q2 '18

Operating Cash Flow TTM

-18M -12M -6M 0 6M 12M 18M Q3 '21: -13.8M Q4 '21: -15.6M Q1 '22: -17.1M Q2 '22: -15.6M Q3 '22: -14.6M Q4 '22: -15.2M Q1 '23: -12.9M Q2 '23: -12.1M Q3 '23: -11.1M Q4 '23: -8.9M Q1 '24: -10.1M Q2 '24: -11.7M Q3 '24: -12.5M Q4 '24: -12.9M Q1 '25: -10.9M Q2 '25: -10.4M Q3 '25: -11.4M Q4 '25: -12.9M Q1 '26: -13.2M Q2 '26: -14.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-12M -8M -4M 0 4M 8M 12M Q4 '17: -5.4M Q1 '18: -9M Q2 '18: -10.4M Q3 '18: -11.6M Q4 '18: -10.7M Q1 '19: -7.4M Q2 '19: -6.8M Q3 '19: -4.5M Q4 '19: -3.7M Q4 '17 Q2 '18 Q4 '18 Q2 '19 Q4 '19

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q3 '18: 50.2M Q1 '19: 51.1M Q1 '20: 70.1M Q1 '21: 16.2M Q2 '21: 33.5M Q3 '21: 31.4M Q1 '22: 32.5M Q2 '22: 31.2M Q3 '22: 31.4M Q1 '23: 1.1M Q2 '23: 1.3M Q3 '23: 1.4M Q1 '24: 1.4M Q2 '24: 1.7M Q3 '24: 2.2M Q1 '25: 2.3M Q2 '25: 2.8M Q3 '25: 3.9M Q1 '26: 30.3M Q2 '26: 38.8M Q1 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q3 '21: -8.30 Q4 '21: -2.67 Q1 '22: -1.01 Q2 '22: -0.96 Q3 '22: -1.01 Q4 '22: -19.67 Q1 '23: -19.71 Q2 '23: -21.10 Q3 '23: -22.65 Q4 '23: -5.64 Q1 '24: -7.07 Q2 '24: -7.75 Q3 '24: -7.51 Q4 '24: -7.00 Q1 '25: -5.69 Q2 '25: -14.44 Q3 '25: -11.87 Q4 '25: -6.68 Q1 '26: -6.46 Q2 '26: 4.34 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.